
Ischemia Reperfusion Injury - Pipeline Insight, 2024
Description
Ischemia Reperfusion Injury - Pipeline Insight, 2024
DelveInsight’s, “Ischemia Reperfusion Injury - Pipeline Insight, 2024,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Ischemia Reperfusion Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Ischemia Reperfusion Injury: Overview
Ischaemia-Reperfusion injury (IRI) is defined as the paradoxical exacerbation of cellular dysfunction and death, following restoration of blood flow to previously ischaemic tissues. Reestablishment of blood flow is essential to salvage ischaemic tissues. However reperfusion itself paradoxically causes further damage, threatening function and viability of the organ. IRI occurs in a wide range of organs including the heart, lung, kidney, gut, skeletal muscle and brain and may involve not only the ischaemic organ itself but may also induce systemic damage to distant organs, potentially leading to multi-system organ failure. Reperfusion injury is a multi-factorial process resulting in extensive tissue destruction.
""Ischemia Reperfusion Injury - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ischemia Reperfusion Injury pipeline landscape is provided which includes the disease overview and Ischemia Reperfusion Injury treatment guidelines. The assessment part of the report embraces, in depth Ischemia Reperfusion Injury commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ischemia Reperfusion Injury collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ischemia Reperfusion Injury R&D. The therapies under development are focused on novel approaches to treat/improve Ischemia Reperfusion Injury.
This segment of the Ischemia Reperfusion Injury report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ischemia Reperfusion Injury Emerging Drugs
- Treprostinil: United Therapeutics
- Combination of 5-ALA and Sodium Ferrous Citrate: SBI Pharmaceuticals
Further product details are provided in the report……..
Ischemia Reperfusion Injury: Therapeutic Assessment
This segment of the report provides insights about the different Ischemia Reperfusion Injury drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Ischemia Reperfusion Injury
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Ischemia Reperfusion Injury: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ischemia Reperfusion Injury therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ischemia Reperfusion Injury drugs.
Ischemia Reperfusion Injury Report Insights
- Ischemia Reperfusion Injury Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ischemia Reperfusion Injury drugs?
- How many Ischemia Reperfusion Injury drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ischemia Reperfusion Injury?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ischemia Reperfusion Injury therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ischemia Reperfusion Injury and their status?
- What are the key designations that have been granted to the emerging drugs?
- United Therapeutics
- SBI Pharmaceuticals
- Aphios Corporation
- Celdara Medical
- Intercept Pharmaceuticals
- Revive Therapeutics
- Amyndas Pharmaceuticals
- Aptorum Group Ltd
- Argenx
- Balmes Transplantation SAS
- Bolder Bio Technology
- CFM Pharma
- Everon Biosciences
- Gero Discovery
- Glucox Biotech AB
- Ischemix
- Lee’s Pharmaceutical Holdings Limited
- LG Chem
- New Horizons Pharma
- Stealth BioTherapeutics
- Treprostinil
- Combination of 5-ALA and Sodium Ferrous Citrate
- AH-190P2
- APP-103TM
- INT-767
- Cannabidiol
- MTP-131
- gemigliptin
- NLS-3
- ARGX-117
- CMX-2043
- Anfibatide
- BBT-059
- VANADIS
- Rapatar
Table of Contents
50 Pages
- Introduction
- Executive Summary
- Ischemia Reperfusion Injury: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Ischemia Reperfusion Injury – DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- Comparative Analysis
- Combination of 5-ALA and Sodium Ferrous Citrate: SBI Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Treprostinil: United Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Ischemia Reperfusion Injury Key Companies
- Ischemia Reperfusion Injury Key Products
- Ischemia Reperfusion Injury- Unmet Needs
- Ischemia Reperfusion Injury- Market Drivers and Barriers
- Ischemia Reperfusion Injury- Future Perspectives and Conclusion
- Ischemia Reperfusion Injury Analyst Views
- Ischemia Reperfusion Injury Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.